Healthcare
Scilex Holding Company(SCLXW)
Live Price
Offline$0.136
+0.00% today
1Y Change
+63.51%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $90.00M
- Revenue Growth
- -46.5%
- EPS Growth
- -87.8%
- Dividend Yield
- 0.0%
Coverage: 228 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scilex Holding Company (SCLXW) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $0.14 and up 63.5% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -46.5%, EPS growth of -87.8%, a dividend yield of 0.0%. What stands out right now is revenue -46.5%, EPS -87.8%, free cash flow -81.0% with operating margin -900.4% and ROIC 1032.0%. Valuation is more restrained than many high-expectation growth names at price/sales 3.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SCLXW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-46.5% vs +7.6% peer median
Operating Margin
Below sector median
-900.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 3, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -46.5% and EPS is at -87.8%, with operating margin around -900.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 3, 2026 | โ | +0.0% | +0.0% | โ |
2026 Feb 25, 2026 | +0.0% | +4.7% | +4.4% | -4.7% |
2025 Nov 14, 2025 | +0.0% | -13.0% | -13.7% | -47.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCLXW
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SCLXW Max Drawdown
-83.83%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SCLXW and SPY.
Company Overview
Scilex Holding Company
NASDAQ Global Market
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
- Leadership
- Henry H. Ji
- IPO Date
- Mar 5, 2021
- Employees
- 115
- Street Address
- 960 San Antonio Road
- Mailing
- Palo Alto, CA, 94303
- Region
- Palo Alto, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 516 4310
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.0
- Price/Book
- โ
Growth
- Revenue
- -46.5%
- EPS
- -87.8%
- Free Cash Flow
- -81.0%
Profitability
- Gross Margin
- 59.7%
- Operating Margin
- -900.4%
- Net Margin
- -1330.4%
- ROE
- 190.5%
- ROIC
- 1032.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.